However, in grade IV GBM patients, expression levels of Znf179 in high- and low-risk groups (Fig. 5E) were both much lower than that in grade II glioma patients (Fig. 5C), and there was no significant difference in clinical outcomes (p = 0.291) according to the Kaplan-Meier survival analysis (Fig. 5F). The gene discussed is RNF112; the disease is glioma.